- Net Income: Abbott India‘s net income for 1Q was 3.28 billion rupees, marking a 13% increase year-on-year. This exceeded analysts’ estimates of 3.24 billion rupees.
- Revenue: The company’s revenue reached 15.6 billion rupees, showing a 5.4% rise compared to the previous year. However, this was slightly below the estimated 16.12 billion rupees.
- Total Costs: Total costs for the quarter were 11.9 billion rupees, up 4.4% from the previous year.
- Analyst Recommendations: The company has 5 buy recommendations, 0 holds, and 1 sell recommendation from analysts.
- Historic Comparisons: Comparisons to past results are based on values from the company’s original disclosures.
A look at Abbott India Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbott India Limited, a company manufacturing pharmaceutical and medical products, agrochemicals, and animal health products, showcases a promising long-term outlook based on its Smartkarma Smart Scores. With a solid dividend score of 5, investors can expect consistent and attractive dividend payouts from Abbott India. The company’s strong resilience score of 5 indicates its ability to weather economic uncertainties and challenges, providing stability to investors in the long run.
While Abbott India‘s value and momentum scores stand at 2 and 3 respectively, indicating room for improvement, its growth score of 3 suggests potential for future expansion and development. Investors eyeing a company with dependable dividends and robust resilience may find Abbott India an appealing long-term investment opportunity, with growth prospects on the horizon.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
